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Supplementary Table 1 Demographic information 
 
 
group N f/m Age (years, mean (range)) EDSS (mean (range)) 
CON 11 10/1 36 (24-56) n.a. 
early MS 11 8/3 36 (26-51) 0.9 (0-2) 
CD 8 5/3 38 (27-49) n.a. 
     
p value    - 
early MS vs CON - p = 0.5865 p = 0.9529 - 
CD vs CON - p = 0.2621 p = 0.6840 - 
early MS vs CD - p = 1.0000 p = 0.5618 - 
 
CD: Crohn’s disease; CON: Healthy controls; MS: Multiple Sclerosis; CIS = Clinically Isolated 











Supplementary Table 2 The list of antibodies and barcoding reagents – Panel A 
 
isotope tag target clone / company 
89Y CD45 (live barcode) HI30 / Fluidigm 
113In CD45 (live barcode) HI30 / Biolegend 
115In CD45 (live barcode) HI30 / Biolegend 
141Pr HLA-DR L243 / Fluidigm 
142Nd CD19 HIB19 / Fluidigm 
143Nd NFAT1 D43B1 / Fluidigm 
144Nd CD44 BJ18 / Biolegend 
145Nd CD4 RPA-T4 / Biolegend 
146Nd TNFa Mab11 / Fluidigm 
147Sm CD11c Bu15 / Fluidigm 
148Nd CD16 3G8 / Fluidigm 
149Sm CCl2 5D3-F7 / Biolegend 
150Nd CD86 IT2.2 / Biolegend 
151Eu CD103 Ber-ACT8 / Fluidigm 
152Sm CD95 DX2 / Biolegend 
153Eu TIM3 F38-2E2 / Biolegend 
154Sm CD3 UCHT1 / Fluidigm 
155Gd CD56 B159 / Fluidigm 
156Gd CCR5 NP-6G4 / Fluidigm 
158Gd CD101 BB27 / Fluidigm 
159Tb IRF4 3E4 / Biolegend 
160Gd CD14 RMO52 / eBioscience 
161Dy EMR1 (F4/80) A10 / Bio-Rad 
162Dy CD8a RPA-T8 / Fluidigm 
163Dy TGF-b TW4-2F8 / Biolegend 
 164Dy CD115 9-4D2-1E4 / Biolegend 
165Ho T-bet (PE) eBio4B10/ eBioscience 
166Er IL-10 JES3-9D7 / Fluidigm 
167Er CCR7 G043H7 / Fluidigm 
168Er IFNg B27 / Fluidigm 
169Tm CD33 WM53 / Fluidigm 
170Er - - 
171Yb CCR2 K036C2 / Biolegend 
172Yb CX3CR1 2A9-1 / Fluidigm 
173Yb CD40 5C3 / Biolegend 
174Yb CD62L DREG-56 / Biolegend 
175Lu ADRP polyclonal / non commercial 
176Yb IL-7R A019D5 / Fluidigm 
195Pt CD45 (live barcode) HI30 / Biolegend 
196Pt CD45 (live barcode) HI30 / Biolegend 
198Pt CD45 (live barcode) HI30 / Biolegend 
191Ir DNA - / Fluidigm 
193Ir DNA - / Fluidigm 




Supplementary Table 3 The list of antibodies and barcoding reagents – Panel B 
 
isotope tag target clone / company 
89Y CD45 (live barcode) HI30 / Fluidigm 
113In CD45 (live barcode) HI30 / Biolegend 
115In CD45 (live barcode) HI30 / Biolegend 
141Pr HLA-DR L243 / Fluidigm 
142Nd CD116 4HI / Biolegend 
143Nd IKZF1 Ikaros / Fluidigm 
144Nd CD38 HIT2 / Fluidigm 
145Nd CD18 TS1/18 / Fluidigm 
146Nd CD64 10.1 / Fluidigm 
147Sm CD13 WM15 / FLuidigm 
148Nd Galanin 581403 / Fluidigm 
149Sm CCl2 5D3-F7 / Biolegend 
150Nd MIPb D21-1351 / Biolegend 
151Eu CD68 Y1/82A / Fluidigm 
152Sm TNFa Mab11 / Fluidigm 
153Eu IL-6 MQ2-13A5 / Biolegend 
154Sm CD172a 15-414 / Biolegend 
155Gd CD54 (ICAM1) HA58 / Biolegend 
156Gd PD-L1 29E.2A3 / Fluidigm 
158Gd CD135 BB27 / Fluidigm 
159Tb GM-CSF BVD2-21C11 / Biolegend 
160Gd CD163 GHI/61 / Biolegend 
161Dy GATA6 D61E4 / Fluidigm 
162Dy CD8a RPA-T8 / Fluidigm 
163Dy CXCR3 G025H7 / Fluidigm 
164Dy Arginase-1 658922 / Fluidigm 
165Ho IL-4 (PE) 8D4-8 / Biolegend 
166Er IL-10 JES3-9D7 / Fluidigm 
167Er IRF8 7G11A45 / Biolegend 
168Er CD206 15-2 / Fluidigm 
169Tm CD33 WM53 / Fluidigm 
170Er - - 
171Yb GLUT1 195205 / R&D Systems 
172Yb HK1 3A10 / Thermo Fisher Scientific 
173Yb CD141 1A4 / Biolegend 
174Yb IL-8 (FITC) EH12.2H7 / Fluidigm 
175Lu ADRP polyclonal / non commercial 
176Yb TREM2 237920 / R&D Systems 
195Pt CD45 (live barcode) HI30 / Biolegend 
196Pt CD45 (live barcode) HI30 / Biolegend 
198Pt CD45 (live barcode) HI30 / Biolegend 
191Ir DNA - / Fluidigm 
193Ir DNA - / Fluidigm 
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Supplementary Figure 1 Meta-cluster abundances of the myeloid cell subset (Panel A). (a) Heat map and cluster analysis 
of the myeloid cell population from all samples on the basis of the mean expression of analysed markers using antibody Panel A. 
Identified clusters are indicated by dendrograms. Heat colours show overall marker expression levels (red, high expression; dark 
blue, no expression). The bar graph shows mean frequency (all samples) of each identified cluster as a % of parent (number in 
black) and a % of total cells (number in gray). (b) The Boxplot shows distribution of cluster frequencies (of parent) of the 14 
identified clusters of each individual sample in both studied groups (CON, gray; early MS, red). No significant differences in 
the cluster distribution was observed between the studied group. 
